Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...
FierceBiotech10h
Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s blockbuster Dupixent. Last year, BMS reported a phase 3 trial in eosinophilic ...
precisionmedicineonline1d
Bristol Myers Squibb Focused on Opdivo SubQ Growth as Q4 Precision Product Sales Increase
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
Bristol-Myers Squibb targets $45.5B revenue for 2025 with cost savings and pipeline expansion
Q4 2024 Management View CEO Chris Boerner highlighted a robust performance in Q4 2024, driven by double-digit growth in the company’s growth portfolio, including key products like Breyanzi, Camzyos, ...
BioPharma Dive1d
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...